Lung Disease Drug Testing Complete Global Approval Sought

Posted 27 August 2012 | By

The final stage of testing for a lung disease drug is finished, and GlaxoSmithKline (GSK) said it will seek global market approval, according to a Reuters report.

GSK said the drug, LAMA/LABA, showed positive results in patients with chronic obstructive pulmonary disease (COPD). The company plans to present the full results from four late-stage trials at future scientific meetings.

Reuters reports GSK wants to develop a successor to Advair, a lung drug that was reportedly worth $8 billion to the company. The wire service said the new next-gen drug will be going up against Pfizer's Spiriva and an experimental drug from Novartis, which could be worth $5 billion per year in sales.

Read more:

Reuters - GSKcompletes trials for combination lung drug


Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Most Viewed Articles